News and Announcements
OncoSil Medical Recruits Second Subject at Monash Health Melbourne for Global Pancreatic Clinical Study Programme
- Published May 11, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that Monash Health has recruited the second subject for its global clinical study program in pancreatic cancer. The second subject has completed all baseline assessments, and will now commence one month of chemotherapy prior to implantation with the OncoSil™ device.
KEY TAKEAWAYS:
- Secondsubjectrecruited for global clinical study in pancreatic cancer by MonashHealth, Melbourne
- This subject is the second in a total of 20 subjects required to meet the Supplemental data request to secure CE Marking
- First subject implanted with the OncoSil™ device on April 24 at Monash Health, Melbourne
OncoSil Chief Medical Officer Dr Ashish Soman commented: “We are pleased with the recruitment efforts and engagement to date by MonashHealth as our lead Australian trial site, and continue to work closely with their team to progress additional patient recruitment for this important global study.”
OncoSil Medical is a medical device company seeking to advance radiation for cancer patients.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
